Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

11.7K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
11.7K
T Cell Types and Functions01:24

T Cell Types and Functions

1.6K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.6K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

5.3K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
5.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

780
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
780
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same author

TOX drives CD4<sup>+</sup> T<sub>H</sub>1 effector function, antitumor immunity and autoimmune pathology.

Nature immunology·2026
Same author

TCF1<sup>lo</sup> CD8 T cells proliferate and persist autonomously in tumors.

bioRxiv : the preprint server for biology·2026
Same author

Pre-division TCF1 drop determines long-term CD8 T cell fates.

bioRxiv : the preprint server for biology·2025
Same author

MDR1 promotes CD8 T cell persistence in tumors and protects against cytotoxic chemotherapy.

bioRxiv : the preprint server for biology·2025
Same author

A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma.

Cancer discovery·2025

Related Experiment Video

Updated: Oct 29, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K

CD8+ T cell differentiation and dysfunction in cancer.

Mary Philip1, Andrea Schietinger2

  • 1Vanderbilt Center for Immunobiology, Vanderbilt-Ingram Cancer Center, Department of Medicine/Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. mary.philip@vumc.org.

Nature Reviews. Immunology
|July 13, 2021
PubMed
Summary

Despite CD8+ T cells targeting cancer, tumors often progress. This review explores T cell dysfunction in cancer and factors influencing immunotherapy response, crucial for improving cancer treatment outcomes.

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.0K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

23.0K

Related Experiment Videos

Last Updated: Oct 29, 2025

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.2K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

7.0K
Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

23.0K

Area of Science:

  • Immunology
  • Cancer Biology
  • Oncology

Background:

  • CD8+ T cells are present in tumors but often fail to eliminate cancer cells.
  • Current immunotherapies like checkpoint blockade show promise but have limited long-term efficacy for many patients.
  • Understanding T cell dysfunction is key to overcoming treatment resistance.

Purpose of the Study:

  • To review the differentiation of CD8+ T cells into dysfunctional states during cancer development.
  • To compare T cell dysfunction with other hyporesponsive T cell states.
  • To discuss factors influencing T cell heterogeneity and response to immunotherapy.

Main Methods:

  • Literature review of CD8+ T cell function in cancer.
  • Analysis of T cell dysfunction and hyporesponsiveness.
  • Exploration of spatio-temporal factors in tumor microenvironments.

Main Results:

  • CD8+ T cell dysfunction is a significant barrier to effective anti-tumor immunity.
  • Tumorigenesis drives T cells towards states of hyporesponsiveness.
  • Heterogeneity in T cell states within tumors complicates treatment prediction.

Conclusions:

  • Identifying biomarkers for immunotherapy response is critical.
  • Understanding the mechanisms of T cell dysfunction can guide the development of novel therapeutic strategies.
  • Further research is needed to predict patient response and identify responsive T cell subsets.